Factor Va-Targeting Aptamer Inhibits Prothrombinase Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant drugs face challenges in balancing therapeutic activity with immunogenicity and reversibility, particularly in managing thrombotic risks without effectively targeting Factor Va (FVa), a critical cofactor in the coagulation pathway.
Innovation Solution
Development of aptamers that specifically bind to Factor V and FVa, inhibiting their procoagulant activity by disrupting the prothrombinase complex formation, thereby preventing blood clot formation without requiring active site targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anticoagulant drugs target the common pathway of coagulation, then thrombin generation is disrupted and anticoagulant activity is achieved, but immunogenicity increases and reversibility is poor
Solution Approach 1:
The patent changes the target parameter from thrombin (enzyme active site) to FVa (cofactor protein structure). This parameter change allows the aptamer to bind to a different molecular target with different immunogenic properties, reducing immune response while maintaining anticoagulant efficacy through disruption of the prothrombinase complex
Solution Approach 2:
The aptamer acts as an intermediary molecule that binds to FVa and prevents its interaction with FXa in the prothrombinase complex. This intermediary approach allows indirect inhibition of thrombin generation without directly targeting thrombin itself, thereby reducing immunogenicity while preserving anticoagulant activity
2Reliability
If current anticoagulant drugs target the common pathway of coagulation, then thrombin generation is disrupted and anticoagulant activity is achieved, but reversibility is poor or irreversible
Solution Approach 1:
The aptamer therapy enables periodic or controllable anticoagulant action through regulated administration and dosing. The reversible binding to FVa allows the anticoagulant effect to be turned on and off as needed, providing periodic action rather than irreversible inhibition, which facilitates ease of repair in case of hemorrhage
Solution Approach 2:
The reversible nature of aptamer-FVa binding creates a feedback mechanism where anticoagulant activity can be monitored and adjusted. If bleeding occurs, the aptamer can be discontinued or reversed, allowing natural hemostasis to recover, providing a feedback loop for safety management
3Reliability
If FVa activity is reduced to prevent thrombotic events, then thrombotic risk is managed, but thrombin generation is impaired and bleeding risk increases
Solution Approach 1:
The aptamer exerts partial inhibition of FVa activity rather than complete blockade. By binding to FVa and preventing prothrombinase complex formation, the aptamer achieves sufficient anticoagulant effect to prevent thrombosis while allowing residual FVa activity to maintain normal hemostasis, thus managing thrombotic risk without excessive bleeding risk
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively prolong clotting times and reduce thrombin generation, offering a safer and more targeted anticoagulant approach for preventing thrombotic events while being potentially reversible.
Implementation Method 1
aptamers that specifically bind to Factor V and FVa, inhibiting their procoagulant activity by disrupting the prothrombinase complex formation
Data Source
AI summary
Provided herein are Factor V/Factor Va-targeting aptamer compositions and antidote compositions targeting such aptamer compositions. Methods for preventing blood clots using such compositions are also provided.